Acumen Pharmaceuticals, Inc.
جودة البيانات: 83%
ABOS
NASDAQ
Manufacturing
Chemicals
KWD 2.47
▼
KWD 0.04
(-1.59%)
القيمة السوقية: 182.34 M
السعر
KWD 2.53
القيمة السوقية
182.34 M
نطاق اليوم
—
نطاق 52 أسبوعًا
—
حجم التداول
—
فتح —
متوسط 50 يوم / 200 يوم
—
متوسط 50 يوم / 200 يوم
—
Quick Summary
النقاط الرئيسية
Debt/Equity of 0.33 — conservative balance sheet
Negative free cash flow of -115.54 M
النمو
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
الجودة
Return on Equity
-115.42%
أقل من متوسط القطاع (-54.47%)
ROIC-71.28%
Net MarginN/A
Op. MarginN/A
الأمان
Debt / Equity
0.33
أعلى من متوسط القطاع (0.30)
Current Ratio6.02
Interest Coverage-29.32
التقييم
PE (TTM|NTM)
-1.50 | -1.77
أقل من متوسط القطاع (-1.49)
P/B Ratio1.96
EV/EBITDAN/A
Dividend YieldN/A
تاريخ السعر
الاتجاهات المالية
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1385 نظير)
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1385 نظير)| المقياس | السهم | وسيط القطاع |
|---|---|---|
| P/E | -1.5 | -1.5 |
| P/B | 2.0 | 1.6 |
| ROE % | -115.4 | -54.5 |
| Net Margin % | — | -41.5 |
| Rev Growth 5Y % | — | 1.9 |
| D/E | 0.3 | 0.3 |
السعر المستهدف للمحللين
5 محللين
Buy
الحالي
KWD 2.47
المستهدف
KWD 7.40
KWD 4.00
KWD 8.00
KWD 10.00
التوقعات
مكرر الربحية المستقبلي
-1.77
ربحية السهم المستقبلية
-KWD 1.39
الإيرادات المقدّرة
0.0
تقديرات الأرباح
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| FY2027 |
-KWD 1.39
-KWD 1.39 – -KWD 1.39
|
0.0 | 1 |
| FY2026 |
-KWD 1.88
-KWD 1.88 – -KWD 1.88
|
0.0 | 1 |
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| 2026 Q2 |
-KWD 0.46
-KWD 0.46 – -KWD 0.46
|
0.0 | 1 |
| 2026 Q1 |
-KWD 0.46
-KWD 0.46 – -KWD 0.46
|
0.0 | 1 |
مفاجآت الأرباح
آخر 4 أرباع
| الربع | EPS المقدر | EPS الفعلي | المفاجأة |
|---|---|---|---|
| Q42025 | -KWD 0.56 | -KWD 0.41 | +26.3% |
| Q32025 | -KWD 0.68 | -KWD 0.44 | +35.2% |
| Q22025 | -KWD 0.52 | -KWD 0.68 | -31.1% |
| Q12025 | -KWD 0.55 | -KWD 0.48 | +12.1% |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -121.34 M |
| ROE | -115.42% | ROA | -77.25% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -115.54 M |
| ROIC | -71.28% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0.33 | Current Ratio | 6.02 |
| Interest Coverage | -29.32 | Asset Turnover | N/A |
| Working Capital | 110.20 M | Tangible Book Value | 93.17 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -1.50 | Forward P/E | -1.77 |
| P/B Ratio | 1.96 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -63.37% | ||
| Market Cap | 182.34 M | Enterprise Value | 166.16 M |
| Per Share | |||
| EPS (Diluted TTM) | -2.00 | Revenue / Share | N/A |
| FCF / Share | -1.60 | OCF / Share | -1.60 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 95.22% |
| SBC-Adj. FCF | -125.31 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -121.34 M | -102.33 M | -52.37 M | -42.86 M | -100.61 M |
| EPS (Diluted) | -2.00 | -1.71 | -1.08 | -1.06 | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -123.83 M | -114.02 M | -61.14 M | -45.24 M | -19.58 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 104.89 M | 93.80 M | 42.32 M | 32.36 M | 12.31 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | — | — | — | — |
| Interest Expense | 4.22 M | 4.07 M | 581,000.0 | — | — |
| Income Tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 122.83 M | 238.99 M | 310.13 M | 196.59 M | 230.33 M |
| Total Liabilities | 52.40 M | 57.18 M | 43.15 M | 7.81 M | 5.15 M |
| Shareholders' Equity | 70.43 M | 181.82 M | 266.97 M | 188.78 M | 225.18 M |
| Total Debt | 31.16 M | 29.42 M | 29.90 M | — | — |
| Cash & Equivalents | 53.99 M | 35.63 M | 66.89 M | — | 122.16 M |
| Current Assets | 122.25 M | 178.31 M | 246.62 M | 180.33 M | 198.66 M |
| Current Liabilities | 30.01 M | 27.61 M | 12.97 M | 7.81 M | — |
{"event":"ticker_viewed","properties":{"ticker":"ABOS","listing_kind":"stock","pathname":"/stocks/abos","exchange":"NASDAQ","country":"US"}}